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Abstract
Endoglin is a glycoprotein with TGF-jS binding capacity and is predominantly expressed on endothelial cells. In 
psoriasis, TGF-/3 has appeared to play a role in the extravasation of peripheral blood mononuclear cells via the 
endothelium. In order to find out more about the role of endoglin in psoriasis, immunohistochemical staining with 
PN-E2, a novel anti-endoglin, and of PAL-E, recognizing vascular endothelium, was carried out in psoriatic involved, 
psoriatic uninvolved and normal skin. The expression of the antigens was assessed semi-quantitatively using a five- 
point scale. In psoriatic involved skin, a high endoglin expression was found. In psoriatic uninvolved skin, however, 
we found that endoglin expression was significantly decreased compared with normal skin. The relevance of these 
findings to the pathogenesis of psoriasis is discussed.
Keywords: Psoriasis; PN-E2
1. Introduction
The role of the endothelium in the pathogenesis 
of psoriasis has been discussed by several authors
Abbreviations; DMEC, dermal microvascular endothelial 
cells; HEV, high endothelial venules; IL, interleukin; LTB4, 
leukotriene B4; mAb, monoclonal antibody; PBMC, peripheral 
blood mononuclear cells; PMN, polymorphonuclear leuko­
cytes; TGF-0, transforming growth factor beta; TNF, tumor 
necrosis factor.
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[1-7]. In the chronic psoriatic plaque a tortuous 
dilated microvasculature constitutes the histo­
logical pattern which is familiar to every derma- 
topathologist. The ultrastructural changes of the 
endothelium consist of intrapapillary capillaries 
with a predominantly venous character and bridg­
ed fenestrations [1,2,4,5]. Other groups reported 
on so-called high endothelial venules (HEV) that 
form the site of preference for the binding of T- 
lymphocytes to endothelium and their subsequent 
migration into the surrounding tissue [&]. In the
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marginal zone of spreading psoriatic plaques an 
increased bloodflow, assessed by laser Doppler 
flowmetry and an increase of endothelial alkaline 
phosphatase activity, has been reported to precede 
the appearance of the overt clinical lesion [9,10]. 
In the distant uninvolved skin Braverman and 
Sibley claimed to have observed vasodilatation [3], 
whereas Heng et ah reported the presence of HEVs 
which are absent in normal skin [8]. Also, the 
capillary resistance of the uninvolved skin in 
psoriasis appeared to be decreased compared with 
normal skin [11].
The aim of the present communication was to 
investigate to what extend endoglin expression 
coincides with psoriatic involvement and possibly 
find out more about its meaning. Expression of en­
doglin is considerably upregulated under inflam­
matory conditions and in skin lesions where 
endothelial cell proliferation occurs [12]. Endoglin 
is a glycoprotein which has been associated with 
adhesion processes [13] and which has transform­
ing growth factor beta (TGF-/3) binding capacity 
[14]. In psoriatic skin, the role of TGF-/3 is not yet 
completely clarified, although it was found that 
TGF-/3 does not influence the adhesiveness of the 
peripheral blood mononuclear cells to the dermal 
microvascular endothelial cells as it does in normal 
skin [15]. Monoclonal antibodies (mAbs) known 
to react with endoglin are RMAC8, HEC-19,
8E11, 1G2 and 44G4 [13]. However, they do not 
all recognize the same epitope. In this study PN- 
E2, a recently developed Ig-Gl monoclonal anti­
body [12], was used as a marker for endoglin. The 
mAb PAL-E was used as a marker for vascular 
endothelial cells [16,17].
2, Materials and methods
2.1. Volunteers
Six patients and 11 healthy persons volunteered 
and gave their informed consent for this study, 
which was carried out after approval of the local 
Medical Ethical Committee. The patient group 
consisted of 3 females and 3 males, aged between 
28 and 63 years, whereas the group of healthy 
volunteers was composed of 4 females and 7 males, 
whose age varied from 17 to 63 years.
The patients had received neither local anti­
psoriatic treatment for at least 2 weeks nor system­
ic treatment for at least 4 weeks prior to the study. 
None of the healthy volunteers had signs or a his­
tory of skin diseases.
2.2. Biopsies 
From the involved and uninvolved psoriatic 
skin and from the normal skin 4 mm punch- 
biopsies were obtained after local infiltration with
1 ml Xylocain 1% with adrenalin 1:100.000 (Xylo-
cain, Astra, Rijswijk, The Netherlands). After the
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Fig. 1. Normal and psoriatic skin: a. level of PAL-E antigen expression, b. level of endoglin expression.
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biopsies were imbedded in TissueTec OTC Com­
pound (Miles Scientific, Naperville, IL), they were 
snap-frozen in liquid nitrogen and stored at 
-80°C. Subsequently, 7 /¿m frozen sections were 
cut and fixed in acetone for 10 min.
2.3. Monoclonal antibodies
The monoclonal antibody PAL-E (Department 
of Pathology, University Hospital Nijmegen) 
[16,17] was used (1:50 dilution) to visualize the en­
dothelium of the microvasculature. This antibody 
specifically recognizes vascular endothelium and 
does not stain the endothelial lining of lymphatic 
vessels. To assess endoglin expression, the mono­
clonal antibody PN-E2 (Department of Pathology, 
University Hospital Nijmegen, The Netherlands) 
was used (1:20 dilution).
2.4 . Staining procedures
Staining was performed using an indirect im- 
munoperoxidase technique. Negative control 
stainings were included.
In brief, slides were rehydrated in phosphate- 
buffered saline (PBS) with Tween 80 and then 
incubated with a monoclonal antibody for 60 min. 
After three washes with PBS they were incubated 
for 30 min with peroxidase-conjugated rabbit-anti- 
mouse antibody (RAMPO, Dakopatts, Copen­
hagen, Denmark). Three more washes preceded a 
pre-incubation with sodium acetate buffer (pH 
4.9), after which the slides were finally stained with 
freshly prepared 3-amino-9-ethyl-carbazole 200 
mg/1 in sodium acetate buffer and 0.01% H20 2 
(AEC solution). All slides were finally washed 
with demineralized water, counterstained with 
M ayer’s haematoxylin (Sigma, St. Louis, MO) and 
mounted in glycerine gelatine.
2.5 . Histological examination
Slides were studied by light microscopy. Using a 
five-point scale, the staining pattern was assessed 
at the papillar, subpapillar and low dermal region. 
This subdivision corresponded with anatomical 
structures as described in [6,18].
2.6. Statistical analysis
The nonparametrical Mann-Whitney test was
used for statistical evaluation.
3. Results
Preliminary semiquantitative assessments were 
carried out in order to establish the system o f  
scoring. Fig. 2 illustrates the various degrees o f  
expression.
In normal as well as in psoriatic uninvolved skin 
the distribution of the two markers over the three 
compartments showed a consistent pattern in 
which the most pronounced staining was seen in 
the subpapillar region (subpapillar plexus). 
Psoriatic involved skin, however, dem onstrated a 
different pattern. In the papillar region o f lesional 
skin, the degree of staining assessed by PAL-E and 
PN-E2 was markedly increased com pared with 
normal and psoriatic uninvolved skin (Fig, 2). 
Furthermore, in some of the tips o f the dermal 
papillae endoglin expression on the microvascular 
endothelium was more pronounced.
In the subpapillar and low dermal region o f  
psoriatic uninvolved skin a statistically significant 
decrease in the occurrence o f  PAL-E staining was 
seen (P = 0.016 and P  = 0.027 respectively, see 
Table 1). Remarkably, a statistically significant 
decrease in PN-E2 staining was seen at all levels o f  
the psoriatic uninvolved skin compared with no r­
mal skin (P  = 0.031, P  = 0.004 and P  = 0.035, see 
Table 1).
To determine whether this decrease was merely 
due to a lower vascularization grade in general o r  
due to a relatively decreased am ount of activated 
endothelium, the ratios of endoglin and PAL-E 
expression were estimated. This was done for all 
levels of the normal and the psoriatic uninvolved 
skin (see Table 2). As previously shown, an in­
creased endoglin expression in dermal capillaries is 
associated with endothelial activation [12]. It was
Table 1
^-values (Mann-Whitney test) comparing immunohisto- 
chemical staining in normal skin and uninvolved skin of 
psoriatic patients
Papillar Subpapillar Low dermal
PAL-E 0.315 0,016 0.027
PN-E2 0.031 0.004 0.035
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Fig. 2. Scoring (papillar level) of endoglin expression (125 X): a. 1 = minimal staining, b. 2 = moderate staining, c. 3 = marked stain' 
ing, d. 4 = extensive staining.
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now found that at the papillar level of psoriatic 
uninvolved skin (Table 2) there was less endoglin 
expressing endothelium compared with normal 
skin (P < 0.01), suggesting less activated endo­
thelium.
4. Discussion
In the normal skin the distribution of PAL-E 
and PN-E2 was for the greater part comparable. 
PAL-E and PN-E2 both showed staining that was
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Table 2
Ratios of endoglin expression and PAL-E antigen expression in normal and psoriatic uninvolved skin
Papillar Subpapillar Low dermal
Normal skin 0.9 db 0.2 0.7 ±0.1 0.9 db 0.1
Psoriatic uninvolved skin 0.3 ± 0.2 0.6 ±  0.1 0.9 ±  0.2
restricted to endothelial cells except for some 
staining of the basal epidermis by PAL-E, as al­
ready described in [16]. In the clinically uninvolv­
ed skin both antibodies showed a decreased 
binding compared with normal skin, PN-E2 
demonstrating the most pronounced decrease
(Table 1).
In order to determine the levels of endothelial 
endoglin expression, the ratios of endoglin and 
PAL-E antigen expression were calculated. In the 
papillar region a relative decrease of endoglin ex­
pression was observed (see Table 2), Taking into 
account, however, the fact that PN-E2 stains the 
endothelial lining of both venous and arterial 
capillaries, venules, veins and probably also of 
lymphatic vessels, it seems not completely correct 
to relate it to PAL-E, which reacts predominantly 
with endothelial cells of medium and small sized 
veins and venules, but not at all or only weakly 
with those of arteries and arterioles and not with 
lymphatic endothelium.
As mentioned above, PN-E2 is a recently 
developed marker for endoglin, a RGD-con- 
taining glycoprotein predominantly expressed on 
the luminal membrane of endothelial cells, activa­
ted monocytes and macrophages and syn- 
citiothrophoblasts. I t  has been shown that this 
antigen is considerably upregulated under inflam­
matory conditions such as psoriasis and in condi­
tions with endothelial cell proliferation such as 
granulation tissue and cutaneous melanoma [12].
Endoglin seems to play a role in adhesion pro­
cesses [13] and shares regions of sequence identity 
with betaglycan, a major binding protein for TGF- 
J8. It binds TGF-j31 and TGF-/33 with high affinity, 
but fails to bind TGF-j32 [14], It is attractive to 
hypothesize that the large amount of endoglin in 
psoriatic involved skin acts as a scavenger by bind­
ing TGF-/3 and thus could modulate TGF-0 inter­
action with its signaling receptors [15]. However, 
so far it cannot be excluded that endoglin might 
enhance TGF-j3 presentation under some condi­
tions [14]. It is remotely possible that some pep­
tides bind TGF-/3 and might modulate TGF-/3 
activity, whereas other peptides leave TGF-/3 
activity unaffected.
Wong et al. [19] found that after a single appli­
cation of LTB4 significantly fewer intraepidermal 
neutrophils were present in psoriatic uninvolved 
skin than in normal skin. Furthermore, repeated 
applications of LTB4 gave significantly lower 
amounts of intraepidermal neutrophils than a sin­
gle application [19]. These findings were confirm­
ed by Lammers and Van De Kerkhof [20] and 
suggest some sort of restraining mechanism for the 
extravasation of polymorphonuclear leukocytes 
(PMN) in psoriatic uninvolved skin in vivo. TGF- 
/3 has a restraining influence on the extravasation 
of peripheral white bloodcells [15]. An increased 
availability of functional TGF-/3 in psoriatic unin­
volved skin may contribute to this decreased ex­
travasation of PM N 's. In psoriatic uninvolved 
skin, the low amount of endoglin will be saturated 
with TGF-0 sooner than the endoglin in normal 
skin. This could indeed mean that the remaining 
TGF-/3 can prevent further extravasation of white 
blood cells, which could explain the difference in 
responsiveness of normal and psoriatic skin to 
LTB4 application. On the other hand, the increas­
ed expression of endoglin in lesional skin might 
prevent TGF-/3 availability and hence be a per­
missive factor for psoriatic inflammation.
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